Johnson Financial Group Inc. Increases Position in Johnson & Johnson $JNJ

Johnson Financial Group Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,672 shares of the company’s stock after purchasing an additional 1,349 shares during the period. Johnson Financial Group Inc.’s holdings in Johnson & Johnson were worth $9,573,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of JNJ. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $35,000. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the 1st quarter worth $48,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson in the first quarter worth $52,000. Finally, Vermillion & White Wealth Management Group LLC boosted its position in Johnson & Johnson by 66.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after buying an additional 150 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.5%

NYSE:JNJ opened at $207.75 on Thursday. The company has a 50-day moving average price of $190.05 and a 200-day moving average price of $172.75. The stock has a market cap of $500.53 billion, a price-to-earnings ratio of 20.05, a P/E/G ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $207.81.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price objective for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Four research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.